Literature DB >> 19006141

Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore.

Ann R Hermone1, James C Burnett, Jonathan E Nuss, Lyal E Tressler, Tam L Nguyen, Bogdan A Solaja, Jonathan L Vennerstrom, James J Schmidt, Peter Wipf, Sina Bavari, Rick Gussio.   

Abstract

A search query consisting of two aromatic centers and two cationic centers was defined based on previously identified small molecule inhibitors of the botulinum neurotoxin serotype A light chain (BoNT/A LC) and used to mine the National Cancer Institute Open Repository. Ten small molecule hits were identified, and upon testing, three demonstrated inhibitory activity. Of these, one was structurally unique, possessing a rigid diazachrysene scaffold. The steric limitations of the diazachrysene imposed a separation between the overlaps of previously identified inhibitors, revealing an extended binding mode. As a result, the pharmacophore for BoNT/A LC inhibition has been modified to encompass three zones. To demonstrate the utility of this model, a novel three-zone inhibitor was mined and its activity was confirmed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006141     DOI: 10.1002/cmdc.200800241

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  18 in total

1.  In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin.

Authors:  Tzuu-Wang Chang; Michael Blank; Pavithra Janardhanan; Bal Ram Singh; Charlene Mello; Michael Blind; Shuowei Cai
Journal:  Biochem Biophys Res Commun       Date:  2010-05-07       Impact factor: 3.575

2.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

3.  Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Authors:  Alan R Jacobson; Michael Adler; Nicholas R Silvaggi; Karen N Allen; Genessa M Smith; Ross A Fredenburg; Ross L Stein; Jong-Beak Park; Xiaochuan Feng; Charles B Shoemaker; Sharad S Deshpande; Michael C Goodnough; Carl J Malizio; Eric A Johnson; Sabine Pellett; William H Tepp; Saul Tzipori
Journal:  Toxicon       Date:  2017-07-08       Impact factor: 3.033

4.  Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Authors:  Bing Li; Steven C Cardinale; Michelle M Butler; Ramdas Pai; Jonathan E Nuss; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Bioorg Med Chem       Date:  2011-10-26       Impact factor: 3.641

5.  Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease.

Authors:  Jonathan E Nuss; Yuxiang Dong; Laura M Wanner; Gordon Ruthel; Peter Wipf; Rick Gussio; Jonathan L Vennerstrom; Sina Bavari; James C Burnett
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

6.  Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite.

Authors:  Garry R Smith; Dejan Caglič; Petr Capek; Yan Zhang; Sujata Godbole; Allen B Reitz; Tobin J Dickerson
Journal:  Bioorg Med Chem Lett       Date:  2012-04-11       Impact factor: 2.823

7.  The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.

Authors:  Shuowei Cai; Paul Lindo; Jong-Beak Park; Kruti Vasa; Bal Ram Singh
Journal:  Toxicon       Date:  2009-12-07       Impact factor: 3.033

8.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

9.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

10.  4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.

Authors:  Igor M Opsenica; Mikloš Tot; Laura Gomba; Jonathan E Nuss; Richard J Sciotti; Sina Bavari; James C Burnett; Bogdan A Solaja
Journal:  J Med Chem       Date:  2013-07-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.